Feed PBIGF
PB
Paradigm Biopharmaceuticals Limited PBIGF OTC · Healthcare · Australia
$0.01 +0.00% +$0.00
Summary
11 / 100 · Bulios Score
Valuation 32Growth 0Profitability 2Quality 0Debt 17Stability 19
What speaks for it
- It holds more cash than debt: $15.4M against $7.50M.
What to watch
- The company made a loss over the last 12 months.
- For every 100 AUD of shareholders' equity it carries 216 AUD of debt.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (AUD)
2022202320242025202620272028
Diluted EPS (AUD)
2022202320242025202620272028
- Analyst estimate
Revenue grew by 31% a year over 5 years.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $56.3M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $15.4M
Debt $7.50M
Free cash flow over 12 months $0.00
It holds more cash than debt. The debt score is low because of the debt-to-equity ratio (2.2x).
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.